FA Chapter 10 IAS 38 Intangible Assets (student)
FA Chapter 10 IAS 38 Intangible Assets (student)
Chapter 10
IAS 38 Intangible Assets
© ACCA
© ACCA
1
2/20/2024
© ACCA 3
Definition
© ACCA 4
2
2/20/2024
© ACCA 5
© ACCA 6
3
2/20/2024
• Computer software
• Patents and licences (exclusive rights to use a process, product or
name)
© ACCA 7
• Development cost
© ACCA 8
4
2/20/2024
Amortisation
The amortizable (depreciable) amount should be allocated
systematically over the best estimate of useful life. The amortisation
period:
© ACCA 9
Amortisation
The carrying amount (Intangible Asset Cost – Accumulated
Amortisation) is reduced to reflect the consumption of economic benefits
over time. The following factors should be considered:
© ACCA 10
5
2/20/2024
Amortisation
• expected competition
• maintenance required
• period of control (e.g. the legal limit on a lease)
• dependency on the useful lives of other assets
© ACCA 11
Amortisation
Amortisation Method
© ACCA 12
6
2/20/2024
Amortisation
Amortisation Method
© ACCA 13
Amortisation
Residual Value
© ACCA 14
7
2/20/2024
© ACCA 15
CR Acc. amortisation
Intangible Asset – Acc.
Asset reduces the value of
Amortisation (SFP)
IA
© ACCA 16
8
2/20/2024
Activity 1
Match the incomplete statement in the left column to the
corresponding statement in the right to complete each sentence.
© ACCA 17
Brock Co spent a further $1m in the second quarter of 20X5 and the
FSA approved Brock Co’s reapplication for a licence on 1 July 20X5.
Brock Co then spent a further $1.5m developing the product range
before its launch on 1 October 20X5. The new product line is expected
to generate revenues in excess of $20m and have a useful life of five
years.
© ACCA 18
9
2/20/2024
© ACCA 19
© ACCA 20
10
2/20/2024
© ACCA 21
© ACCA 22
11
2/20/2024
For example, a company that makes medicines carries out research into
the use of herbs to cure headaches. This research results in the
company finding one herb with unique properties for curing headaches.
The company then uses this research and develops a headache pill using
this herb, which is tested and then made ready to sell to the public.
© ACCA 23
© ACCA 24
12
2/20/2024
© ACCA 25
© ACCA 26
13
2/20/2024
© ACCA 27
© ACCA 28
14
2/20/2024
© ACCA 29
© ACCA 30
15
2/20/2024
CR Bank (Asset)
decreased to pay for
Bank/Cash (SFP) Asset
development cost
© ACCA 31
The capitalised development cost will be amortised over its useful life
and charged to the Statement of Profit or Loss. Development
expenditure has no residual value since no active market exists (each
development will be unique).
If any of the above criteria is not met, the development cost cannot be
capitalised and must be treated as an expense in the Statement of Profit
or Loss.
Individual Account Category Explanation
DR Development (SPL) Expense Development
(Expense) has
increased
CR Bank (Asset) has
Bank/Cash (SFP) Asset
decreased
© ACCA 32
16
2/20/2024
© ACCA 33
Example 1
On 1 April 20X6, Brooks established a new research and development
unit to acquire scientific knowledge on the use of synthetic chemicals for
pain relief. The following expenses were incurred during the year ended
31 March 20X7.
© ACCA 34
17
2/20/2024
Example 1
1. Purchase of building for $400,000. The building is to be depreciated
on a straight-line basis at the rate of 4% per annum on cost.
CR Bank $400,000
© ACCA 35
Example 1
At the year-end, the depreciation charge is $400,000 x 4% = $16,000
and should be expensed off by:
© ACCA 36
18
2/20/2024
Example 1
2. Wages and salaries of research staff are $2,355,000.
Research costs must always be expensed off. The double entry is:
CR Bank $2,355,000
© ACCA 37
Example 1
3. Development cost that meets the criteria to be capitalised has been
calculated to be $60,000. It is amortised using the straight-line
method of 25% per annum.
CR Bank $60,000
© ACCA 38
19
2/20/2024
Example 1
The amortisation charge for the year is $60,000 x 25% = $15,000
© ACCA 39
Example 1
The total amount expensed in the statement of profit or loss is:
$2,401,000
© ACCA 40
20
2/20/2024
Activity 3
In its first year of trading, which ended 31 July 20X6, Eco-chem incurred
the following expenditures on research and development (none related
to the cost of property, plant and equipment).
© ACCA 41
Activity 3
Commercial production and sales of the headache pill commenced on 1
April 20X6 and are expected to produce steady, profitable income for
five years before being replaced. Adequate resources exist to achieve
this.
© ACCA 42
21
2/20/2024
© ACCA 43
© ACCA 44
22
2/20/2024
© ACCA 45
© ACCA 46
23
2/20/2024
Example 2
The disclosure note for intangible assets in the financial statements is as
follows:
© ACCA 47
Summary
© ACCA 48
24
2/20/2024
Summary
© ACCA 49
25